Successful treatment with bortezomib for refractory cryoglobulinemic vasculitis triggered by ischemic non-obstructive coronary artery disease
CEN Case Reports · 2025
DOI: 10.1007/s13730-024-00963-2 ↗Kurz gefasst
Fallbericht in der Zeitschrift CEN Case Reports, 2025. Verfasst von Yui Ohta und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-Cho, Itabashi, Tokyo, 173-0015, Japan. Hauptthemen laut MEDLINE: Bortezomib, Coronary Artery Disease, Cryoglobulinemia, Vasculitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Type I and mixed cryoglobulinemic vasculitis differ in pathophysiology, clinical presentation, and therapeutic response. We report a case of refractory cryoglobulinemic vasculitis diagnosed following ischemic non-obstructive coronary artery disease (INOCA). The patient presented with dyspnea, as well as abdominal pain due to ischemic enteritis, purpura, and renal failure requiring dialysis. Despite the patient's IgG λ-type monoclonal gammopathy of undetermined significance (MGUS) and negative hepatitis C virus, the presence of rheumatoid factor (RF) activity and the possibility of IgM involvement were suggested by cryoglobulin analysis and strong glomerular IgM deposition. The condition was diagnosed as mixed cryoglobulinemia, and various immunomodulatory treatments, including methylprednisolone, rituximab and plasmapheresis, were administered without achieving cryoglobulin negativity. However, treatment with bortezomib and dexamethasone ultimately led to cryoglobulin negativity and clinical improvement although the patient was not weaned off dialysis, resulting in remission of the cryoglobulinemic vasculitis. This case suggests that bortezomib, a proteasome inhibitor, may be a promising treatment for refractory cryoglobulinemic vasculitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-Cho, Itabashi, Tokyo, 173-0015, Japan.
- Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-Cho, Itabashi, Tokyo, 173-0015, Japan.
- Molecular Regulation of Aging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-Cho, Itabashi, Tokyo, 173-0015, Japan.
- Division of Nephrology and Endocrinology, Tohoku Medical and Pharmaceutical University Hospital, 35-2 Sakae-Cho, Itabashi, Tokyo, 173-0015, Japan.
- Department of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-Cho, Itabashi, Tokyo, 173-0015, Japan. takashi_takei@tmghig.jp.
ORCID-Profile: Takashi Takei
Zitieren
APA
Ohta, Y., Tsuchiya, T., Oka, M., Tachibana, M., Kondo, Y., Fukushima, K., Matsuno, S., Yamanaka, N., Suzuki, N., Komatsu, A., Rokutan, H., Yumura, W., Arai, T., Ishigami, A., Itabashi, M., & Takei, T. (2025). Successful treatment with bortezomib for refractory cryoglobulinemic vasculitis triggered by ischemic non-obstructive coronary artery disease. CEN Case Reports. https://doi.org/10.1007/s13730-024-00963-2
Vancouver
Ohta Y, Tsuchiya T, Oka M, Tachibana M, Kondo Y, Fukushima K, et al. Successful treatment with bortezomib for refractory cryoglobulinemic vasculitis triggered by ischemic non-obstructive coronary artery disease. CEN Case Reports. 2025. doi:10.1007/s13730-024-00963-2
BibTeX
@article{Ohta2025,
author = {Ohta, Yui and Tsuchiya, Takaaki and Oka, Masatoshi and Tachibana, Moriaki and Kondo, Yoshitaka and Fukushima, Kaoruko and Matsuno, Shiho and Yamanaka, Noriko and Suzuki, Noriyuki and Komatsu, Akiko and Rokutan, Hirofumi and Yumura, Wako and Arai, Tomio and Ishigami, Akihito and Itabashi, Mitsuyo and Takei, Takashi},
title = {Successful treatment with bortezomib for refractory cryoglobulinemic vasculitis triggered by ischemic non-obstructive coronary artery disease},
journal = {CEN Case Reports},
year = {2025},
doi = {10.1007/s13730-024-00963-2}
}
EUVIMED